Advertisement

Topics

SYGNIS Pharma AG Company Profile

13:13 EDT 19th September 2017 | BioPortfolio

SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research, development and marketing of innovative therapies for the treatment of disorders of the Central Nervous System. These include stroke, amyotrophic lateral sclerosis (ALS) and neurological disorders resulting from injuries of the brain or spinal cord. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available.

Location

Im Neuenheimer Feld 515
Heidelberg
69120
Germany

Contact

Phone: +49 6221 454 6
Fax: +49 6221 454 700
Email: contact@sygnis.de


News Articles [2345 Associated News Articles listed on BioPortfolio]

DGAP-Adhoc: SYGNIS AG: SYGNIS AG schließt Bezugsangebot und Privatplatzierung erfolgreich ab (deutsch)

SYGNIS AG: SYGNIS AG schließt Bezugsangebot und Privatplatzierung erfolgreich ab DGAP-Ad-hoc: SYGNIS AG / Schlagwort(e): Kapitalerhöhung SYGNIS AG: SYGNIS AG schließt Bezugsangebot und Privatplatz....

SYGNIS AG changes in management and supervisory board

SYGNIS AG announced changes to the management team and supervisory board. Dr. Heikki Lanckriet (previously Co-CEO) will become sole CEO of SYGNIS AG and will also retain his role as Chief Scientific O...

DGAP-Adhoc: SYGNIS AG: SYGNIS AG plant Übernahme der profitablen Innova Biosciences Ltd. für 8 Mio. Euro in bar und bis zu 3,5 Mio. Aktien (deutsch)

SYGNIS AG: SYGNIS AG plant Übernahme der profitablen Innova Biosciences Ltd. für 8 Mio. Euro in bar und bis zu 3,5 Mio. Aktien DGAP-Ad-hoc: SYGNIS AG / Schlagwort(e): Ankauf SYGNIS AG: SYGNIS AG p.....

SYGNIS AG - Successful acquisition of Innova Biosciences

SYGNIS AG announced that the Company has successfully completed its acquisition of Innova Biosciences Ltd. SYGNIS AG paid EUR 10.8 million, consisting of EUR 8 million in cash and 2 million shares of ...

DGAP-News: SYGNIS AG: SYGNIS AG plant Übernahme der profitablen Innova Biosciences Ltd. für 8 Mio. Euro in bar und bis zu 3,5 Mio. Aktien (deutsch)

SYGNIS AG: SYGNIS AG plant Übernahme der profitablen Innova Biosciences Ltd. für 8 Mio. Euro in bar und bis zu 3,5 Mio. Aktien DGAP-News: SYGNIS AG / Schlagwort(e): Ankauf SYGNIS AG: SYGNIS AG pla.....

DGAP-News: SYGNIS AG: SYGNIS AG gibt Veränderungen bei Management und Aufsichtsrat bekannt (deutsch)

SYGNIS AG: SYGNIS AG gibt Veränderungen bei Management und Aufsichtsrat bekannt DGAP-News: SYGNIS AG / Schlagwort(e): Personalie SYGNIS AG: SYGNIS AG gibt Veränderungen bei Management und Aufsicht.....

Sygnis acquires Innova Biosciences for up to €8mm in cash, plus stock

Sygnis Pharma AG acquired Innova Biosciences Ltd. (bioconjugation products and services) for €8mm ($9mm) in cash and up to 3.5mm in shares.

Sygnis AG: 3-Stufen-Analyse vom 07.07.2017

Seit dem letzten Handelstag hat sich der Kurs von Sygnis um -1,92% verändert. Der aktuelle Kurs beträgt 1,58€. Der Kurs der Sygnis-Aktie änderte sich in der letzten Woche um 1,81% und seit Jahre...

Drugs and Medications [238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [31 Associated PubMed Articles listed on BioPortfolio]

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.

In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innova...

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Clinical Trials Series - Large Pharma.

AI-powered drug discovery captures pharma interest.

Clinical Trials [73 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Companies [717 Associated Companies listed on BioPortfolio]

SYGNIS Pharma AG

SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research, development an...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

Laurantis Pharma Oy

Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies, ...

FranceMed Pharma

FranceMed Pharma is a Research, Development, FMCG Manufacturer and Global Marketing Company established since 1981. FranceMed Pharma owns Magicool® brand and the world-wide patents and technology. Fr...

More Information about "SYGNIS Pharma AG" on BioPortfolio

We have published hundreds of SYGNIS Pharma AG news stories on BioPortfolio along with dozens of SYGNIS Pharma AG Clinical Trials and PubMed Articles about SYGNIS Pharma AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SYGNIS Pharma AG Companies in our database. You can also find out about relevant SYGNIS Pharma AG Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Stroke - Cerebrovascular Disease (CVA)
A stroke is a serious medical condition that occurs when the blood supply to part of the brain is cut off. Strokes are a medical emergency and prompt treatment is essential because the sooner a person receives treatment for a stroke, the less damage is ...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Corporate Database Quicklinks



Searches Linking to this Company Record